Program
trontinemab
Also written as “Trontinemab” and “RO7126209”.
Its studies are mostly in Alzheimer Disease, led by Hoffmann-La Roche.
Furthest: phase 3, since Sep 10, 20255 company-led studies, 4 open or runningNext primary completion: Jul 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 54 open or running | phase 3since Sep 10, 2025 | Jul 16, 2019 | Jul 31, 2027phase 2 · NCT04639050 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6102 trontinemab
, phase 3, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2019First study: phase 1 study in Alzheimer DiseaseFirst studyNCT04023994 · 36 enrolled · United States
- Nov 17, 2020Phase 2 study in Alzheimer DiseaseNCT04639050 · 241 enrolled · United States, Australia, Canada and more
- Sep 10, 20252 phase 3 studies in Alzheimer DiseaseNCT07170150, NCT07169578
- Jul 17, 2026Phase 3 study in Alzheimer DiseaseNCT07717411 · 1,600 planned · United States, Argentina, Australia and more
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Alzheimer DiseaseNCT04639050
- Feb 16, 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT07170150
- Feb 16, 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT07169578
- Jul 30, 2032Primary completion: phase 3 study in Alzheimer DiseaseNCT07717411
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07717411Alzheimer Disease · United States, Argentina, Australia and more | 3 | Recruiting | Jul 30, 2032 | 1,600 |
| NCT07170150Alzheimer Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 16, 2028 | 1,060 |
| NCT07169578Alzheimer Disease · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Feb 16, 2028 | 1,101 |
| NCT04639050Alzheimer Disease · United States, Australia, Canada and more | 2 | Active, not recruiting | Jul 31, 2027 | 241 |
| NCT04023994Alzheimer Disease · United States | 1 | Completed | Jul 17, 2020 | 36 |
How it is read
Names in the registry
- “Trontinemab”, 3 entries
- “RO7126209”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.